Federated Hermes, Inc. Chinook Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $370,251 - $765,504	-19,842 Reduced 1.58%	1,232,546 $47.4 Million
Q1 2023 May 08, 2023	BUY	$21.53 - $26.8 $7.84 Million - $9.75 Million	363,934 Added 40.96%	1,252,388 $29 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $14 Million - $20.5 Million	750,191 Added 542.58%	888,454 $23.3 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $2.42 Million - $3.23 Million	138,263 New	138,263 $2.72 Million
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $246,146 - $343,519	-18,099 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$14.17 - $19.11 $232,076 - $312,983	16,378 Added 951.66%	18,099 $282,000
Q4 2020 Feb 12, 2021	BUY	$11.9 - $20.91 $20,479 - $35,986	1,721 New	1,721 $27,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.